Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of FCN-338 combined with azacitidine or chemotherapy in myeloid malignancies
CTR20231176Phase 2Active
- Sponsor
- Fochon Biosciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LOXO-338 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Fochon Biosciences. Started Aug 2023; status: active.
02
Drugs
LOXO-338
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on CTR20231176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231176.